Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of HR091506 in Primary Gout
NCT05347498Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Apr 2022
- Primary completion
- Jul 2022
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of HR091506 in primary gout and hyperuricemia (2 arms), sponsored by Hengrui. Primary endpoint: Proportion of subjects with serum uric acid level < 360μmol/L at Day 29. Status: unknown.
02
Drugs
HR091506
03
Conditions
primary gouthyperuricemia
Beyond the preview
Go deeper on NCT05347498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05347498.